Table 2 Univariate analysis for overall survival and progression free survival in patients with PTCL-NOS

Age

   < 60 years

69.4

1.54 (0.92-2.58)

0.100

11.9

1.00 (0.62-1.62)

0.976

   ≥ 60 years

18.9

13.8

Gender

   Male

30.0

1.24 (0.73-2.11)

0.422

12.1.

0.91 (0.55-1.51)

0.732

   Female

27.5

15.2

Performance status

   0-1

57.4

4.09 (2.10-8.00)

< 0.001

14.5

2.28 (1.16-4.46)

0.016

   2-4

6.3

3.6

B symptom

   Absent

38.5

1.45 (0.84-2.50)

0.178

14.7

1.31 (0.79-2.16)

0.282

   Present

15.6

7.1

Stage

   1-2

69.4

1.63 (0.93-2.87)

0.086

19.1

1.68 (1.02-2.77)

0.041

   3-4

16.6

9.5

Extranodal involvement

   0-1

69.4

2.10 (1.24-3.54)

0.005

18.1

2.08 (1.29-3.35)

0.003

   ≥ 2

11.5

8.1

Bone marrow involvement

   Negative

57.4

1.62 (0.93-2.79)

0.084

14.5

1.68 (1.02-2.76)

0.039

   Positive

10.2

7.3

LDH

   Normal

NR

2.89 (1.67-5.00)

< 0.001

16.0

1.69 (1.06-2.68)

0.025

   Elevated

11.5

8.8

IPI

   L, LI

NR

3.96 (2.36-6.66)

< 0.001

18.1

2.34 (1.47-3.74)

< 0.001

   HI, H

8.1

8.1

PIT

   Group 1-2

76.1

2.78 (1.67-4.62)

< 0.001

15.2

1.69 (1.06-2.69)

0.026

   Group 3-4

10.1

9.4

ALC

   ≥ 1.0 × 10⁹/l

69.4

2.19 (1.30-3.67)

0.003

18.1

3.01 (1.14-3.02)

0.012

   < 1.0 × 10⁹/l

15.5

7.0